# LinkedIn post — draft (Inflammaging / Patent 52)

> Educational / thought-leadership angle, mirroring the fibrosis post. Copy the
> body below; attach the graphic; the repo URL is already in the body. Variants
> and posting notes follow.

---

## Post body

A more selective drug won't fix aging inflammation. I built a tool to show why — and it's the same trap I hit with fibrosis, one layer up.

When a drug that clears senescent cells has bad side effects, the instinct is always the same: make it cleaner. More selective. Hit only what you want.

For senolytics and senomorphics — the drugs that target cellular senescence and the inflammation of aging — that instinct is only half right.

Some side effects are **off-target**: the drug hits proteins it was never meant to. Those you can engineer away with selectivity.

But the worst effects come from the **right target in the wrong cell.** BCL-xL inhibition kills senescent cells beautifully — and in platelets, causes dangerous thrombocytopenia. Silencing the inflammatory secretome via NF-κB or JAK works — and immunosuppresses the very immune cells you need for host defense. Same target, wrong place. No amount of selectivity separates those.

And a third class is worse still: some harm is **intrinsic to killing senescent cells at all** — you also lose the beneficial, transient senescence that helps wounds heal.

So the lever that actually works isn't selectivity. It's **localization** — confining the drug to the senescent cell (a β-galactosidase-activated prodrug, a platelet-sparing degrader). I turned the whole causal map (drug → node → cell → outcome) into an interactive designer. Run it forward from a molecule, or backward from the outcome you want. An exhaustive search of ~98,000 designs says only cell-targeted delivery ever reaches zero predicted adverse effects.

(It's a conceptual model — illustrative weights, not validated potencies — built to make the trade-off *legible*, not to rank real compounds.)

🔗 Try the tool, code, and preprint — links in the first comment.

Built in collaboration with Claude — it did the analysis, coding, and figures from my direction.

Is localization an underrated design axis in senotherapeutics?

#Longevity #Senolytics #Inflammaging #DrugDiscovery #ComputationalBiology #DrugDelivery #AgingResearch

---

## First comment (post immediately after publishing)

Links:
▶️ Run it in your browser (no install): https://glenritschel.github.io/inflammaging-drug-designer
💻 Code + reproducible analysis: https://github.com/glenritschel/inflammaging-drug-designer
📄 Preprint: https://doi.org/10.5281/zenodo.21696338
📑 Provisional patent specification: https://doi.org/10.5281/zenodo.21696296

---

## Alternate opening hooks

- "The same drug that clears an aging cell can crash your platelet count. That one fact reshapes how you'd design a senolytic."
- "Everyone says: make the senolytic more selective. It quietly fails for the same reason it failed in fibrosis — here's the interactive version."
- "I filed a patent today on a simple idea: for anti-aging drugs, *where* a drug acts matters more than *what* it hits."

## Posting notes

- **First line is everything** on LinkedIn — it's all that shows before "…see more." Keep the hook on line 1, then a blank line.
- **Native image beats a link.** Attach the graphic directly. Put the GitHub URL in the body and/or the first comment.
- **Put the repo link in the first comment** too — some report better reach when the post body has no external link.
- **Length:** ~150–220 words performs well; trim the parenthetical to tighten.
- **IP check:** the provisional (US Application 64/121,903) is filed as of 2026-07-29, so public disclosure now is safe for the filed subject matter. If the post describes anything beyond what the spec covers, confirm before posting.
